Gregory Abel, MD, MPH, MFA

Gregory Abel, MD, MPH, MFA

Associate Professor of Medicine, Dana-Farber Cancer Institute
Member, HMS Center for Bioethics

Gregory Abel, MD, MPH, MFA is an outcomes researcher and hematologic oncologist at Dana-Farber Cancer Institute (DFCI) and Harvard Medical School. He helps run DFCI’s Older Adult Hematologic Malignancy (OHM) geriatric hematology research program, serves as Co-Chair of the DFCI Ethics Advisory Committee, and directs DFCI’s Clinical Ethics Service. The Abel research lab applies health services research methods to understand the experiences of patients with blood cancers and develop interventions to improve their care. Dr. Abel is also interested in evaluating how cancer and its therapies affect outcomes such as function and quality of life. Through his work and collaboration with researchers in oncology, hematology, geriatrics, bioethics, and energy balance, he aims to ameliorate the impact of hematologic malignancies and their treatment from diagnosis to the end of life.

Publications View
Prevalence and Tolerance of Prognostic Uncertainty Among Thoracic Oncologists.
Authors: Authors: Habib AR, Chen R, Magnavita ES, Jaung T, Awad MM, Odejide O, Abel GA.
Oncologist
View full abstract on Pubmed
Advances in Management for Older Adults With Hematologic Malignancies.
Authors: Authors: Rosko AE, Cordoba R, Abel G, Artz A, Loh KP, Klepin HD.
J Clin Oncol
View full abstract on Pubmed
Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?
Authors: Authors: Abel GA, Kim HT, Hantel A, Steensma DP, Stone R, Habib A, Ho VT, Wadleigh M, El-Jawahri A, Alyea EP, DeAngelo DJ, Koreth J, Antin JH, Soiffer RJ, Cutler C.
Leukemia
View full abstract on Pubmed
Model solutions for ethical allocation during cancer medicine shortages.
Authors: Authors: Hantel A, Peppercorn J, Abel GA.
Lancet Haematol
View full abstract on Pubmed
Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review.
Authors: Authors: Chang Y, Guyatt GH, Teich T, Dawdy JL, Shahid S, Altman JK, Stone RM, Sekeres MA, Mukherjee S, LeBlanc TW, Abel GA, Hourigan CS, Litzow MR, Michaelis LC, Alibhai SMH, Desai P, Buckstein R, MacEachern J, Brignardello-Petersen R.
PLoS One
View full abstract on Pubmed
US State Government Crisis Standards of Care Guidelines: Implications for Patients With Cancer.
Authors: Authors: Hantel A, Marron JM, Casey M, Kurtz S, Magnavita E, Abel GA.
JAMA Oncol
View full abstract on Pubmed
Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions.
Authors: Authors: Tanasijevic AM, Revette A, Klepin HD, Zeidan A, Townsley D, DiNardo CD, Sebert M, DeZern AE, Stone RM, Magnavita ES, Chen R, Sekeres MA, Abel GA.
Leuk Lymphoma
View full abstract on Pubmed
Gait speed, survival, and recommended treatment intensity in older adults with blood cancer requiring treatment.
Authors: Authors: Hantel A, DuMontier C, Odejide OO, Luskin MR, Sperling AS, Hshieh T, Chen R, Soiffer R, Driver JA, Abel GA.
Cancer
View full abstract on Pubmed
Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?
Authors: Authors: Abel GA, Kim HT, Hantel A, Steensma DP, Stone R, Habib A, Ho VT, Wadleigh M, El-Jawahri A, Alyea EP, DeAngelo DJ, Koreth J, Antin JH, Soiffer RJ, Cutler C.
Leukemia
View full abstract on Pubmed
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.
Authors: Authors: Sekeres MA, Guyatt G, Abel G, Alibhai S, Altman JK, Buckstein R, Choe H, Desai P, Erba H, Hourigan CS, LeBlanc TW, Litzow M, MacEachern J, Michaelis LC, Mukherjee S, O'Dwyer K, Rosko A, Stone R, Agarwal A, Colunga-Lozano LE, Chang Y, Hao Q, Brignardello-Petersen R.
Blood Adv
View full abstract on Pubmed